Pharma

Novartis NVS

NOVARTIS AGPharmaceutical PreparationsV8

Pipeline — registered trials by phase

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

— · Atherosclerotic Cardiovascular Disease · Active Not Recruiting · est. 2027-05-10

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

— · Renal Function, Liver Transplant · Completed · est. 2016-06

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

— · Diabetes Mellitus, Type 2 · Completed · est. 2006-02

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

— · Hypertension · Completed · est. 2007-08

NVA237 Versus Placebo 12-week Efficacy Study

— · Chronic Obstructive Pulmonary Disease · Completed · est. 2013-10

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

— · Bacterial Meningitis · Completed · est. 2014-04

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

— · Diabetes Mellitus, Type 2 · Completed · est. 2008-05

Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

— · Hypertension · Completed · est. 2007-04

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

— · Influenza · Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

— · Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) · Completed · est. 2020-07-08

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

— · Hypertension · Completed · est. 2008-04

Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

— · Hypertension · Completed · est. 2005-10

Eltrombopag Phase III Study In Chinese Chronic ITP Patients

— · Purpura, Thrombocytopenic, Idiopathic and Hepatitis C · Completed · est. 2014-06-05

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

— · Parkinson's Disease · Completed · est. 2007-09

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

— · Prostatic Neoplasms · Active Not Recruiting · est. 2025-01-13

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

— · Influenza · Completed · est. 2007-12

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

— · Paroxysmal Nocturnal Hemoglobinuria · Completed · est. 2024-10-17

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

— · Hypertension · Completed · est. 2008-02

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

— · Relapsing Forms of Multiple Sclerosis · Completed · est. 2018-10-19

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

— · Non-Small Cell Lung Cancer · Active Not Recruiting · est. 2026-09-03

Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients

— · Renal Transplantation · Completed · est. 2005-11

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

— · Diabetes Mellitus, Type 2 · Completed · est. 2014-02

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

— · Sporadic Inclusion Body Myositis (sIBM) · Completed · est. 2016-08-23

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

— · Oligometastatic Prostate Cancer (OMPC) · Recruiting · est. 2028-04-25

Source: ClinicalTrials.gov (trials where Novartis is lead sponsor; 80 active or completed) and Drugs@FDA (31 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

6-K2026-09-08Report of foreign issuer
6-K2026-09-04Report of foreign issuer
6-K2026-09-01Report of foreign issuer
6-K2026-07-21Report of foreign issuer
6-K2026-06-11Report of foreign issuer
6-K2026-04-28Report of foreign issuer
6-K2026-03-18Report of foreign issuer
424B52026-03-17Prospectus (offering)
FWP2026-03-17FWP
424B52026-03-16Prospectus (offering)
S-82026-02-04Employee stock plan
6-K2026-02-04Report of foreign issuer
6-K2026-02-04Report of foreign issuer
IRANNOTICE2026-02-04IRANNOTICE
20-F2026-02-04Annual report (foreign)
S-8 POS2026-01-16S-8 POS
S-8 POS2026-01-16S-8 POS
S-8 POS2026-01-16S-8 POS
S-8 POS2026-01-16S-8 POS
DFAN14A2026-01-14DFAN14A
DFAN14A2026-01-12DFAN14A
6-K2025-11-25Report of foreign issuer
6-K2025-11-20Report of foreign issuer
6-K2025-11-05Report of foreign issuer
424B52025-11-04Prospectus (offering)
FWP2025-11-04FWP
424B52025-11-03Prospectus (offering)
DFAN14A2025-10-28DFAN14A
SC TO-T/A2025-10-28SC TO-T/A
DFAN14A2025-10-28DFAN14A
6-K2025-10-28Report of foreign issuer
DFAN14A2025-10-27DFAN14A
DFAN14A2025-10-27DFAN14A
DFAN14A2025-10-27DFAN14A
6-K2025-10-27Report of foreign issuer
SC TO-T/A2025-10-22SC TO-T/A
SC TO-T/A2025-10-20SC TO-T/A
6-K2025-09-30Report of foreign issuer
SC TO-T2025-09-29SC TO-T
SC TO-C2025-09-09SC TO-C

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.